Intrathecal chemotherapy in lymphomatous meningitis

Fabio Canova, Dario Marino, Chiara Trentin, Caterina Soldà, Cristina Ghiotto, Savina Maria Luciana Aversa

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Central Nervous System (CNS) involvement in lymphoma can occur whether at diagnosis or, more often, at the progression or recurrence of disease and the most frequent clinical manifestation is lymphomatous meningitis (LM). The first risk factor for LM development is the histotype, with the highest incidence for highly aggressive non-Hodgkin's lymphomas (NHL) such as Burkitt's lymphoma (BL) and lymphoblastic lymphoma/acute lymphoblastic leukemia (LBL/ALL) and the lowest for indolent NHL. LM prophylaxis in aggressive NHL (other than BL and LBL/ALL) is a much debated question, because the identification of specific risk factors remains controversial. Moreover, there is not a consensus if the LM prophylaxis should consist of systemic chemotherapy (CT), intrathecal (i.t.) CT or both. In case of LM, the i.t. CT has a key role, but there is not a consensus on treatment schedule. Newer intensified regimens and rituximab lead to reconsider the whole approach to LM.

Original languageEnglish
Pages (from-to)127-134
Number of pages8
JournalCritical Reviews in Oncology/Hematology
Volume79
Issue number2
DOIs
Publication statusPublished - Aug 2011

Fingerprint

Meningitis
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Drug Therapy
Non-Hodgkin's Lymphoma
Burkitt Lymphoma
Lymphoma
Appointments and Schedules
Central Nervous System
Recurrence
Incidence

Keywords

  • Central nervous system
  • Hodgkin
  • Intrathecal
  • Lymphoma
  • Lymphomatous meningitis
  • Meningeal

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

Intrathecal chemotherapy in lymphomatous meningitis. / Canova, Fabio; Marino, Dario; Trentin, Chiara; Soldà, Caterina; Ghiotto, Cristina; Aversa, Savina Maria Luciana.

In: Critical Reviews in Oncology/Hematology, Vol. 79, No. 2, 08.2011, p. 127-134.

Research output: Contribution to journalArticle

Canova, Fabio ; Marino, Dario ; Trentin, Chiara ; Soldà, Caterina ; Ghiotto, Cristina ; Aversa, Savina Maria Luciana. / Intrathecal chemotherapy in lymphomatous meningitis. In: Critical Reviews in Oncology/Hematology. 2011 ; Vol. 79, No. 2. pp. 127-134.
@article{89b81dfaa9ac406db84a27a8306f95cc,
title = "Intrathecal chemotherapy in lymphomatous meningitis",
abstract = "Central Nervous System (CNS) involvement in lymphoma can occur whether at diagnosis or, more often, at the progression or recurrence of disease and the most frequent clinical manifestation is lymphomatous meningitis (LM). The first risk factor for LM development is the histotype, with the highest incidence for highly aggressive non-Hodgkin's lymphomas (NHL) such as Burkitt's lymphoma (BL) and lymphoblastic lymphoma/acute lymphoblastic leukemia (LBL/ALL) and the lowest for indolent NHL. LM prophylaxis in aggressive NHL (other than BL and LBL/ALL) is a much debated question, because the identification of specific risk factors remains controversial. Moreover, there is not a consensus if the LM prophylaxis should consist of systemic chemotherapy (CT), intrathecal (i.t.) CT or both. In case of LM, the i.t. CT has a key role, but there is not a consensus on treatment schedule. Newer intensified regimens and rituximab lead to reconsider the whole approach to LM.",
keywords = "Central nervous system, Hodgkin, Intrathecal, Lymphoma, Lymphomatous meningitis, Meningeal",
author = "Fabio Canova and Dario Marino and Chiara Trentin and Caterina Sold{\`a} and Cristina Ghiotto and Aversa, {Savina Maria Luciana}",
year = "2011",
month = "8",
doi = "10.1016/j.critrevonc.2010.07.005",
language = "English",
volume = "79",
pages = "127--134",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Intrathecal chemotherapy in lymphomatous meningitis

AU - Canova, Fabio

AU - Marino, Dario

AU - Trentin, Chiara

AU - Soldà, Caterina

AU - Ghiotto, Cristina

AU - Aversa, Savina Maria Luciana

PY - 2011/8

Y1 - 2011/8

N2 - Central Nervous System (CNS) involvement in lymphoma can occur whether at diagnosis or, more often, at the progression or recurrence of disease and the most frequent clinical manifestation is lymphomatous meningitis (LM). The first risk factor for LM development is the histotype, with the highest incidence for highly aggressive non-Hodgkin's lymphomas (NHL) such as Burkitt's lymphoma (BL) and lymphoblastic lymphoma/acute lymphoblastic leukemia (LBL/ALL) and the lowest for indolent NHL. LM prophylaxis in aggressive NHL (other than BL and LBL/ALL) is a much debated question, because the identification of specific risk factors remains controversial. Moreover, there is not a consensus if the LM prophylaxis should consist of systemic chemotherapy (CT), intrathecal (i.t.) CT or both. In case of LM, the i.t. CT has a key role, but there is not a consensus on treatment schedule. Newer intensified regimens and rituximab lead to reconsider the whole approach to LM.

AB - Central Nervous System (CNS) involvement in lymphoma can occur whether at diagnosis or, more often, at the progression or recurrence of disease and the most frequent clinical manifestation is lymphomatous meningitis (LM). The first risk factor for LM development is the histotype, with the highest incidence for highly aggressive non-Hodgkin's lymphomas (NHL) such as Burkitt's lymphoma (BL) and lymphoblastic lymphoma/acute lymphoblastic leukemia (LBL/ALL) and the lowest for indolent NHL. LM prophylaxis in aggressive NHL (other than BL and LBL/ALL) is a much debated question, because the identification of specific risk factors remains controversial. Moreover, there is not a consensus if the LM prophylaxis should consist of systemic chemotherapy (CT), intrathecal (i.t.) CT or both. In case of LM, the i.t. CT has a key role, but there is not a consensus on treatment schedule. Newer intensified regimens and rituximab lead to reconsider the whole approach to LM.

KW - Central nervous system

KW - Hodgkin

KW - Intrathecal

KW - Lymphoma

KW - Lymphomatous meningitis

KW - Meningeal

UR - http://www.scopus.com/inward/record.url?scp=79960177559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960177559&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2010.07.005

DO - 10.1016/j.critrevonc.2010.07.005

M3 - Article

VL - 79

SP - 127

EP - 134

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 2

ER -